Elix Inc. and the University of Vienna have signed a joint research agreement aimed at advancing drug discovery using AI technologies.

Sprint Bioscience AB has entered into an agreement to use Lilly Tunelab, Eli Lilly and Co.’s AI-based drug discovery platform, to support work on its research portfolio.

Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism spectrum disorder and facioscapulohumeral muscular dystrophy programs. The company’s pipeline also includes programs for myotonic dystrophy and Huntington’s disease.

Thyora Therapeutics has launched with a mission to leverage next-generation covalent chemistry to accelerate clinical translation and create therapies for unmet medical needs.

Human cytomegalovirus (CMV) is a clinical challenge in infants and immunocompromised individuals, since no licensed vaccine exists. Vaccine development is complex due to several factors, including viral latency, genomic complexity and immune evasion, among others. Evaxion A/S recently presented data on its proprietary AI-immunology platform used to create the EVX-V1 vaccine for CMV infection.

While biomedical resources in the form of specialized tools, hundreds of thousands of published papers and huge repositories of ‘omics, health records and other data, are growing exponentially, discovery is getting slower and more expensive. That is the perspective from which scientists at Stanford University approached the development of their artificial intelligence (AI) research assistant Biomni.

Mindbeam AI has leveraged generative AI to accelerate the discovery of novel pain therapeutics predicted to have improved liver safety compared to acetaminophen.

While biomedical resources in the form of specialized tools, hundreds of thousands of published papers and huge repositories of ‘omics, health records and other data, are growing exponentially, discovery is getting slower and more expensive. That is the perspective from which scientists at Stanford University approached the development of their artificial intelligence (AI) research assistant Biomni.

A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell engager (TCE) for autoimmune disorders in a potential $1.62 billion deal.

Some proteins embedded in the structure of prions may have antimicrobial activity, according to a study led by scientists at the University of Pennsylvania. An AI analysis of millions of fragments from prion-related proteins has revealed more than a thousand peptides that disrupt bacterial membranes and reduce infection in animal models, suggesting these proteins could be an unexpected source of new antibiotics.